drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (allogeneic CAR T cells)
drug_description
Allogeneic, donor-derived gene-modified chimeric antigen receptor T-cell (CAR-T) product targeting mesothelin (MSLN); designed as an off-the-shelf CAR-T therapy that binds MSLN on tumor cells and induces T-cell activation and cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic, gene-modified T cells expressing a chimeric antigen receptor that binds mesothelin (MSLN) on tumor cells, activating CAR signaling to induce T-cell effector functions and cytotoxic killing (perforin/granzyme release and cytokine secretion) independent of the native TCR.
drug_name
CHT102
nct_id_drug_ref
NCT06717022